Modeling cost of treatment with new topical treatments for glaucoma: Results from france and the United Kingdom

International Journal of Technology Assessment in Health Care

Volumn 15, Issue 1, 1999, Pages 207-219

  Kobelt, Gisela ^a   Jönsson, Linus ^a  

^a NONE

Author keywords

Cost; Glaucoma; Modeling

Indexed keywords

COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; GLAUCOMA; INTRAOCULAR PRESSURE; PROBABILITY; REVIEW; STATISTICAL ANALYSIS; TREATMENT PLANNING;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; FRANCE; GLAUCOMA; GREAT BRITAIN; HUMANS; INTRAOCULAR PRESSURE; MARKOV CHAINS; MODELS, ECONOMETRIC; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT FAILURE;

EID: 0344867029     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462399015299     Document Type: Review

References (25)

1. Alm, A., Stjernschantz, J., & the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. Ophthalmology, 1995, 102, 1743-52.
2. Bendel, R. E., Juzych, M. S., Hughes, B. A., et al. The additive effect of latanoprost to a maximum-tolerated medical regimen in medically uncontrollable glaucoma patients. American Academy of Ophthalmology, Chicago, October 1996. Scientific Poster 66.
3. Camras, C. B., & the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology, 1996, 103, 138-47.
4. Canadian Coordinating Office for Health Technology Assessment: Guidelines for economic evaluation of pharmaceuticals: Canada. 1st ed. Ottawa, Ontario, Canada: CCOHTA, November 1994.
5. Cantor, L. B., & Burke, J. Brimonidine: Drug evaluation. Experimental Opinion on Investigational Drugs, 1997, 6, 1063-83.
6. Commonwealth of Australia. Guidelines for the pharmaceutical industry in preparation of submissions to the Pharmaceutical Benefits Advisory Committee: Including submissions involving economic analysis. Woden (ACT) Department of Health, Housing and Community Services, 1990.
7. Cottle, R. W., & Begg, I. S. Effectiveness and costs of antiglaucoma medications. Journal of Toxicology - Cutaneous and Ocular Toxicology, 1988, 7, 283-93.
8. Finckler, S. A. The distinction between costs and charges. Annals of Internal Medicine, 1982, 96, 102-09.
9. Gerdtham, U. G., Hågå, A., Karlsson, G., Kobelt, G., & Jönsson, B. Observational costing study in open angle primary glaucoma in Sweden and the USA. EFI Research Paper No. 6566. Stockholm: Stockholm School of Economics, 1996.
10. Gerdtham, U. G., Williamson, T. E, Hågå, A., Kobelt. G., & Jo̊nsson, B. Observational costing study in open angle primary glaucoma: Results for Canada. EFI Research Paper No. 6569. Stockholm: Stockholm School of Economics, 1997.
11. Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996.
12. Heijl, A. Effect of IOP on the visual field in ocular hypertension and glaucoma. Ophthalmology, 1989, 13, 119-24.
13. Hitchings, R. A. Primary surgery for primary open angle glaucoma - Justified or not? British Journal of Ophthalmology, 1993, 77, 445-48.
14. Kobelt, G., Gerdtham, U. G., & Alm, A. Cost of treating primary open-angle glaucoma and ocular hypertension. Journal of Glaucoma, 1998, 7, 95-104.
15. Kobelt, G., Gerdtham, U. G., & Krieglstein, G. K. Direct costs of glaucoma management following initiation of medical therapy in Germany. Graefe's Archives, 1999, (in press).
16. Lundberg, L., Wettrell, K., & Linnér, E. Ocular hypertension: A prospective twenty-year follow-up study. Acta Ophthalmologica, 1987, 65, 705-08.
17. Mao, K. L., Stewart, C. S., & Shields, M. B. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open angle glaucoma. American Journal of Ophthalmology, 1991, 111, 51-55.
18. PCS Health Systems: Re: Solve 500 Data Model, Glaucoma Drug Claims, December 1, 1995 to December 31, 1997. Data on file, Pharmacia and Upjohn, Kalamazoo, MI.
19. Pharmacia and Upjohn, Dept. of Ophthalmics, Uppsala, Sweden. Data on file, 1997.
20. Pharmacia and Upjohn, Dept. of Ophthalmics, Uppsala, Sweden. Data on file, 1997.
21. Quigley, H.A. Open-angle glaucoma (review). New England Journal of Medicine, 1993, 15, 1097-106.
22. Strahlman, E., Tipping, M. S., & Vogel, M. D. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt). timolol and betaxolol. Archives of Ophthalmology, 1995, 113, 1009-16.
23. Tielsch, J. M., Sommer, A., Katz, J., et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA, 1991, 266, 369-74.
24. Use of beta blocker in the treatment of glaucoma: A cost-benefit study. PMA cost-effectiveness of pharmaceuticals. American Pharmaceutical Manufacturers Association, Report 8, 1984.
25. Watson, P., Stjernschantz, J., & the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology, 1996, 103, 126-37.